To observe the effect of unani medicine in patients having little flow during periods.

Effect Of Unani Formulation in Oligomenorrhoea - An Observational Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/012193

Enrollment

Registered

2018-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N915- Oligomenorrhea, unspecified Health Condition 2: null- Oligomenorrhoea

Interventions

Intervention1: COMMIPHORA MYRRHA-3gm, JUNIPAROUS COMMUNIS-1gm, RUTA GRAVEOLENS-3gm, RUBIA CARDIFOLIA-3gm SHARBAT BAZOORI-50ml: decoction of 10 gm unani formulation with 50 ml of sharbat buzoori will b

Eligibility

Inclusion criteria

Inclusion criteria: Infrequent menstruation of more than 35days or scanty flow both in amount and duration, Hypothyroidism on treatment & PCOD.

Exclusion criteria

Exclusion criteria: Patients with hyperprolactinaemia,Uterine synechiae, endometrial tuberculosis, ovarian tumours & malignancy,Hypertension, Diabetes mellitus & other systemic diseases,Pregnant women, lactating women and women on IUCDs.

Design outcomes

Primary

Measure	Time frame
Changes in Menstrual pattern:Cycle interval (duration of cycle),Menstruation length (duration of flow) ,No. of pads (amount of flow) Timepoint: BEFORE AND AFTER TREATMENT	—

Secondary

Measure	Time frame
Changes in-PBAC,SF-12 survey to assess QOL. Timepoint: BEFORE AND AFTER TREATMENT	—

Countries

India

Contacts

Public ContactDr Wajeeha Begum

National Institute Of Unani Medicine

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026